FMT

Featured in Ripley's Believe It or Not! This medical advance could save lives but comes with a stomach-churning premise. Source: Forget Red And Blue Pills, Would You Take The Brown Pill?

One of the most prevalent cardiac diseases is cardiac arrhythmia, however the underlying causes are not entirely understood. There is a lot of proof that gut microbiota (GM) and its metabolites have a significant impact on cardiovascular health. In recent decades, intricate impacts of GM on cardiac …

Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease characterized by multiple organ damage accompanied by the over-production of autoantibodies. Decreased intestinal flora diversity and disruption of homeostasis have been proven to be associated with pathogenesis of SLE. …

Systemic lupus erythematosus (SLE) is an autoimmune disease with the characterized presence of autoantibodies and resulting in multiple organ damage, which is incurable and can be lethal. The current treatments are limited and less progress has been made in drug discovery for the last few decades. R …

NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary

Candace Cotto, RN, and Andrew Skinner, MD, discuss the challenges of traditional fecal microbiota transplantation (FMT) in treatment of CDI.

Fecal microbiota transplantation (FMT) is highly effective in preventing recurrent Clostridioides difficile infection. In this review, we discuss its potential mechanisms of action from ecological, microbial mediated metabolic, immunological, and epigenetic perspectives. We also highlight limitations and propose future research directions.

Fecal microbiota transplantation (FMT) is highly effective in preventing recurrent Clostridioides difficile infection (rCDI). However, the mechanisms underpinning its clinical efficacy are incompletely understood. Herein, we provide an overview of rCDI pathogenesis followed by a discussion of potent …

Several studies suggest that butyrate may be important in alleviating gut infections, such as reducing inflammation caused by the healthcare-associated Clostridioides difficile . While studies in both animal models and human studies correlate high levels of butyrate with reduced C. diffici …

FDA approves second microbiome-based C. difficile therapy

Fecal microbiota transplantation (FMT) has achieved satisfactory results in preventing the recurrence of Clostridioides difficile infection, but these positive outcomes have only been partially replicated in other diseases. Several factors influence FMT success, including those related to donors and …

Microbiota therapies offer exciting potential to reduce the burden of recurrent Clostridioides difficile infection, experts say.

A scientific review concluded that fecal microbiota transplantation is more effective than antibiotics against recurrent ‘Clostridioides difficile’ infections; researchers are also investigating its possibilities in mental health and to improve the effect of immunotherapy in cancer

CHICAGO — Treatment with Rebyota did not affect concurrent medication use in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection, Jessica R. Allegretti, MD, MPH, explains in this Healio video. Allegretti presented data at Digestive Disease Week on safety outcomes and concomitant medication changes after treatment with Rebyota (fecal microbiota,

Fecal microbiota transplants are the most effective and affordable treatment for recurrent infections with Clostridioides difficile, an opportunistic bacterium and the most common cause of hospital-acquired intestinal infections. However, attempts to treat chronic noncommunicable diseases such as ulcerative colitis and metabolic syndrome via fecal microbiota transplantation (FMT) have yielded mixed results. Two review articles publishing May 10 in the journal Cell Host and Microbe discuss what we do and don’t know about why FMTs work (when they do).

What is the "optimal formula" for donor selection and feces processing for fecal microbiota transplantation in ulcerative colitis?

Fecal microbiota transplantation (FMT) is highly effective in preventing recurrent Clostridioides difficile infection (rCDI). However, the mechanisms underpinning its clinical efficacy are incompletely understood. Herein, we provide an overview of rCDI pathogenesis followed by a discussion of potent …

Fecal microbiota transplantation (FMT) has achieved satisfactory results in preventing the recurrence of Clostridioides difficile infection, but these positive outcomes have only been partially replicated in other diseases. Several factors influence FMT success, including those related to donors and …

The microbiome plays a vital role in maintaining homeostasis of the intestinal microenvironment and immune response in allogeneic hematopoietic cell transplantation (HCT) recipients. Disruption of the intestinal microbiome has been associated with the development of acute graft-versus-host disease ( …

As a long-term condition that affects the airways and lungs, chronic obstructive pulmonary disease (COPD) is characterized by inflammation, emphysema, breathlessness, chronic cough, and sputum production. Currently, the bronchodilators and anti-inflammatory drugs prescribed for COPD are mostly off-t …

Clostridioides difficile, which causes life-threatening diarrheal disease, is considered an urgent threat to healthcare setting worldwide. The current standards of care solely rely on conventional antibiotic treatment, however, there is a risk of promoting recurrent C. difficile infection (rCDI) bec …

Nature Reviews Drug Discovery - Discover the world’s best science and medicine | Nature.com

Clostridioides difficile, which causes life-threatening diarrheal disease, is considered an urgent threat to healthcare setting worldwide. The current standards of care solely rely on conventional antibiotic treatment, however, there is a risk of promoting recurrent C. difficile infection (rCDI) bec …

Ferring’s Rebyota therapeutic was studied in this population and demonstrated a 79% efficacy.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported initial clinical data about SER-155. SER-155 is an

CHICAGO — In a Healio video exclusive, Ken Blount, PhD, discusses successful restoration of gut microbiota and clonal engraftment as soon as 1 week after treatment with Rebyota in those with recurrent Clostridioides difficile infection. Blount and colleagues sought to quantify and define clonal engraftment and durable microbiome compositional changes with FDA-approved Rebyota (fecal

Featured in Ripley's Believe It or Not! This medical advance could save lives but comes with a stomach-churning premise. Source: Forget Red And Blue Pills, Would You Take The Brown Pill?

Ferring’s Rebyota, which was FDA approved late last year, demonstrated a high efficacy and favorable safety profile in the prevention of recurrent Clostridioides difficile.